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Use of extracorporeal membrane oxygenation for treatment of respiratory failure 
caused by sepsis is controversial because of concerns over survival benefit and 
hemorrhage-related complications. To evaluate the impact of the primary diagnosis 
of sepsis on outcome, we reviewed data from 6853 neonates in the Extracorporeal 
Life Support Organization Registry and defined two groups: group 1 (n = 1060), all 
patients undergoing extracorporeal membrane oxygenation with a primary diagno- 
sis of sepsis; group 2 (n = 5793), those with any other primary diagnosis. A 
multivariate logistic regression analysis that considered 15 variables present before 
extracorporeal membrane oxygenation (including age, sex, birth weight, prior 
cardiopulmonary arrest, arterial blood gas results, and ventilator settings) was used 
to compare outcomes between groups. Survival was not different between the two 
groups (77%, group 1; 82%, group 2; p = 0.2480), although lung recovery was less 
frequent in the patients with sepsis (p = 0.0185). Group I had a higher incidence of 
complications including seizures (odds ratio 1.446, p = 0.0346), cerebral infarct or 
hemorrhage (2.310,p = 0.0001), need for dialysis (1.478,p = 0.0131), hypernatremia 
(2.089, p = 0.0019), hyperbilirubinemia (2.423, p = 0.0001), and dobutamine use 
(1.918, p = 0.0001). Neonates with sepsis are more likely to have neurologic, renal, 
and metabolic complications from extracorporeal membrane oxygenation but may 
still achieve a survival benefit equivalent o those without sepsis. From these data, 
extracorporeal membrane oxygenation should not be withheld from neonates olely 
on the basis of sepsis. Rather, management strategies hould focus on limiting the 
incidence or severity of the common complications. (J TrIORAC CARDIOVASC SURG 
1995;109:419-27) 
Dan M. Meyer, MD (by invitation), Michael E. Jessen, MD (by invitation), 
Dallas, Tex., and the Extracorporeal Life Support Organization, Ann Arbor, Mich. 
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T he development of sepsis in the neonate carries a high mortality because of the potential for 
rapid progression to septic shock with its resultant 
physiologic hanges. 1'2 With group B streptococcal 
sepsis, the most common form of neonatal sepsis in 
the United States, the acute syndrome is character- 
ized by respiratory distress, hypoxemia, vascular 
collapse, disseminated intravascular coagulation, 
and the development of a syndrome of persistent 
pulmonary hypertension with right-to-left shunting. 3 
Before the introduction of extracorporeal mem- 
brane oxygenation (ECMO), management of this 
condition was limited to medical therapy based on 
organism-targeted antibiotic coverage, aggressive 
ventilator management, and vasopressor r inotro- 
pic support. Results of conventional therapy were 
poor when the course was complicated by pulmo- 
nary dysfunction, with predicted mortality rates ap- 
proaching 80%. 4 As a result, some clinicians have 
applied ECMO to the management of the infant 
with sepsis, despite controversy regarding its use in 
septic states. 
Since its introduction in 1975, 5 ECMO has be- 
come the standard of care for neonates with severe 
respiratory failure resulting from meconium aspira- 
tion syndrome, 6' 7 persistent pulmonary hyperten- 
sion of the newborn, s and congenital diaphragmatic 
hernia with persistent fetal circulation. 9 Currently, 
the application of ECMO in neonatal sepsis, al- 
though widely performed, is less accepted because 
of concerns over survival benefit and hemorrhage- 
related morbidity. 1° Other standard therapeutic op- 
tions in the seriously ill neonate are largely ineffec- 
tive, however. To date, available reports have 
involved small numbers of patients in whom ECMO 
was used for the management of sepsis, limiting the 
ability to fully analyze the benefits of this modality 
when other variables are considered. This study was 
undertaken to critically evaluate the effectiveness of
ECMO in neonatal sepsis as reported to the Extra- 
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Fig. 1. Frequency distribution of 6856 neonates subjeeted to ECMO. MAS, Meconium aspiration 
syndrome; CDH, congenital diaphragmatic hernia with persistent fetal circulation; PPHN, persistent 
pulmonary hypertension of the neonate; RDS, respiratory distress yndrome. 
corporeal Life Support Organization (ELSO) Reg- 
istry. 
Methods 
Patients. This study consisted of 6856 neonates (aged 
14 days or less) supported by ECMO between November 
1987 and June 1993 and entered in the ELSO Registry. 
The primary indication for ECMO was available for all 
but three of the patients, and the frequency of each 
indication is presented in Fig. 1. For analysis, the data 
were divided into two groups. Group 1 consisted of all 
patients with a primary diagnosis of neonatal sepsis (n = 
1060), and group 2 included those patients with any other 
primary indication (n = 5793). Of note, 127 members of 
group 1 also carried a secondary diagnosis of sepsis or 
pneumonia or both, and 639 members of group 2 carried 
either secondary diagnosis. The presence of either of 
these secondary diagnoses was not considered in the 
analysis. 
Outeome variables. Outcome variables studied in- 
cluded survival (at time of reporting), recovery (of lung 
function leading to discontinuation f ECMO), and dura- 
tion of ECMO support (in hours). Moreover, 51 ECMO 
complications were available for analysis. Additional vari- 
ables used in the comparison were the volume of packed 
red blood cells, fresh frozen plasma, and platelets admin- 
istered uring the peri-ECMO period and the use of drugs 
(vasoactive agents, bicarbonate, and surfactant) in the 
patients upported by ECMO. The 68 outcome variables 
are listed in Appendix A. 
Pre-ECMO faetors. In addition to the primary indica- 
tion for ECMO, 15 variables were used in the evaluation 
as predictors of outcome from ECMO. These variables 
included patient age at the time of ECMO, sex, birth 
weight, and a history of cardiopulmonary arrest before 
ECMO. Also, the results of the most recent arterial blood 
gas analysis before ECMO, the ventilator parameters of 
the patient immediately before initiation of ECMO, and 
the most recent oxygenation i dex (calculated as [inspired 
oxygen fraction × mean airway pressure x 100]/arterial 
oxygen tension) were used in the analysis. The type of 
ECMO was not included because 89% underwent ECMO 
via a venoarterial technique. The pre-ECMO variables 
used are listed in Appendix B. 
Statistieal analysis. Data were analyzed by means of 
the SAS software package (SAS Institute, Cary, N.C.). A 
univariate analysis of all outcome variables was performed 
initially to compare results between groups 1 and 2. A )(2 
analysis was used for discrete variables, with ap value less 
than 0.05 by two-tailed Fisher's exact test considered 
significant. For continuous variables, Student's t test with 
Welch's approximation for unequal variances was used to 
compare results between the two groups. This analysis was 
also considered significant at a p value of less than 0.05. 
We used additional tests to account for interactions 
between pre-ECMO variables. For dichotomous outcome 
variables, a multivariate stepwise logistic regression anal- 
ysis for each outcome event was performed. The group 
variable plus all variables listed in Appendix B were 
candidates for entry into the model. For each resulting 
model, the group variable was always included, whereas 
only those remaining variables that met the 0.05 signifi- 
cance level were entered. For each element in the model, 
a parameter estimate was calculated from which ap value 
and an odds ratio for the variable were derived. From 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 109, Number 3 
Meyer and Jessen 4 2 1 
Table lA. Outcome variables found to occur significantly more frequently (p < 0.05) in patients with a 
primary diagnosis of sepsis as determined by univariate analysis 
Variable Group 1 Group 2 p Value 
Brain death (%) 
Seizures (%) 
Infarct or hemorrhage byhead ultrasound (%) 
Infarct or hemorrhage byCT/MRI (%) 
Other neurologic problem (%) 
Creatinine > 1.5 mg/dl (%) 
Dialysis/hemofiltration (%) 
Myocardial stunning (%) 
Symptomatic PDA (%) 
Culture-proven secondary infection (%) 
Suspected secondary infection, elevated WBC count (%) 
Other infectious problem (%) 
Na + > 150 mEq/L (%) 
Ca ++ < 6 mg/dl (%) 
Glueose < 40 mg/dl (%) 
Glucose > 240 mg/dl (%) 
pH < 7.20 (%) 
Hyperbilirubinemia (%) 
Dopamine use (%) 
Dobutamine use (%) 
Epinephrine use (%) 
Biearbonate use (%) 
Surfactant use (%) 
2.3 0.9 0.0003 
17.1 12.1 0.0001 
24.9 10.9 0.0001 
6.5 3.0 0.0001 
5.5 3.6 0.0042 
14.1 9.7 0.0001 
18.6 13.0 0.0001 
8.2 6.2 0.0206 
5.0 3.3 0.0112 
13.2 4.2 0.0001 
4.2 1.8 0.0001 
1.9 1.0 0.0182 
6.5 2.6 0.0001 
3.3 1.5 0.0003 
3.3 2.0 0.0104 
3.5 2.1 0.0073 
4.5 1.6 0.0001 
13.6 5.8 0.0001 
81.6 74.0 0.0001 
60.8 46.5 0.0001 
18.7 9.9 0.0001 
54.7 35.9 0.0001 
14.7 9.2 0.0001 
Values are expressed as percentage occurrence foreach group. CT, Computed tomography; MR/, magnetic resonance imaging; PDA, patent ductus arteriosus; 
WBC, white blood cell. 
each model, a p value of less than 0.05 was considered 
significant for the group variable. 
For continuous outcome variables, a stepwise multiple 
regression analysis was performed. All candidate variables 
were the same (Appendix B). Parameter estimates for the 
group variable in the resulting models were calculated and 
statistical significance was defined at the 0.05 level. 
Results 
Overall results. Survival was documented in 
81.3% of the entire group of 6856 neonates. Lung 
recovery leading to separation from ECMO oc- 
curred in 85.3% of the total. Although any individ- 
ual ECMO complication occurred infrequently, at 
least one complication occurred in 5310 patients 
(77.5%) and more than one complication was doc- 
umented in 3095 (54.9%). 
Univariate analysis. A univariate analysis of each 
outcome variable was undertaken to compare the 
1060 neonates with a primary diagnosis of sepsis 
against he remaining 5793 patients. The exact cause 
of sepsis was not available for all patients, but 74% 
of those with documentation of source had group B 
streptococcal sepsis. No other organism represented 
more than 9% of group 1. Outcome variables that 
were found to be significantly different are listed in 
Tables IA and Iß  along with their mean values or 
frequency of occurrence as appropriate. Of note, 
survival was significantly worse in the septic group 
(p = 0.0002) and recovery of lung function was also 
less likely (t9 = 0.0001) by this analysis. Patients 
undergoing ECMO as salvage from sepsis were also 
more likely to have severe neurologic, renal, and 
metabolic problems (see Table LA). Inotropic agents 
and bicarbonate were more frequently adminis- 
tered. Only the development of pneumothorax and 
mechanicalbleeding complications were statistically 
more frequent in the nonseptic group (group 2). 
Administration of red blood cells and fresh frozen 
plasma was also increased in group 2. The duration 
of ECMO was longer in group 2 (p = 0.0006). 
Multivariate analysis. To account for potential 
interactions between pre-ECMO variables, we per- 
formed a stepwise regression for each variable as 
described earlier. Outcome variables that were 
found to be significantly different between the two 
groups at a p value of 0.05 are listed in Tables I IA 
and IIB. As expected, fewer outcomes were signifi- 
cantly different between groups by this analysis. 
In particular, survival was not predicted by sepsis 
(p = 0.2480). Variables that did predict survival 
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Table Iß.  Outcome variables found to occur significantly less frequently (p < 0.05) in patients with a primary 
diagnosis of sepsis as determined by univariate analysis 
Variable Group 1 Group 2 p Value 
Survival (%) 
Lung recovery (%) 
Duration of ECMO (hr) 
Bleeding at cannula site (%) 
Bleeding at other surgical site (%) 
Pneumothorax necessitating treatment (%) 
Red blood ceUs transfused (tal) 
Fresh frozen plasma transfused (ml) 
77.0 82.1 0.0002 
75.9 85.3 0.0001 
133 _+ 86 143 ___ 90 0.0006 
3.9 6.5 0.0012 
2.5 7.2 0.0001 
2.9 5.8 0.0001 
397 _+ 457 554 -~ 824 0.0001 
241 + 351 314 -+ 591 0.0100 
Values are presented aspercentage occurrence for each group or as mean -+ standard deviation as appropriate. 
Table I IA. Outcome variables found to occur significantly more frequently (p < 0.05) in patients with a 
primary diagnosis of sepsis as determined by multivariate analysis 
Variable Parameter stimate Odds ratio p Value 
Seizures 0.3685 1.446 0.0346 
Infarct or hemorrhage by head ultrasound 0.8374 2.310 0.0001 
Other neurologic problem 0.5926 1.809 0.0242 
Dialysis/hemofiltration 0.3909 1.478 0.0131 
Symptomatic PDA 0.5390 1.714 0.0190 
Culture-proven i fection 1.3950 4.035 0.0001 
Na+ > 150 mEq/L 0.7369 2.089 0.0019 
Hyperbilirubinemia 0.8852 2.423 0.0001 
Dobutamine use 0.6513 1.918 0.0001 
Bicarbonate use 0.6027 1.827 0.0001 
Surfactant use 0.4941 1.639 0.0085 
Table IIB. Outcome variables found to occur significantly less frequently (p < 0.05) in patients with a primary 
diagnosis of sepsis as deterrnined by multivariate analysis 
Variable Parameter stimate Odds ratio p Value 
Lung recovery -0.5148 0.598 0.0185 
Bleeding at other surgical site -1.3237 0.266 0.0008 
Pneumothorax necessitating treatment -0.8177 0.444 0.0092 
Other pulmonary problem -1.0025 0.367 0.0120 
included higher birth weight (p = 0.001), absence of 
cardiopulmonary arrest before ECMO (p = 0.002), 
higher arterial pH before ECMO (p = 0.0001), and 
lower ventilator ate required before ECMO (p = 
0.0016). Recovery of lung function was less frequent 
in the septic group (odds ratio 0.598, p = 0.0185). 
Recovery was also predicted by birth weight, most 
recent arterial pH, and previous ventilatory rate. By 
multivariate analysis, fewer complications were sta- 
tistically more common in the septic group. How- 
ever, neurologic, renal, and metabolic factors re- 
mained significant (see Table IIA). In addition to 
the outcome variables listed in Tables I IA  and IIB, 
four dichotomous variables achieved borderline sta- 
tistical significance. These factors, all of which oc- 
curred more frequently in group 1, were serum 
creatinine greater than 1.5 mg/dl (parameter esti- 
mate 0.3049, odds ratio 1.357, p = 0.0771), myocar- 
dial stunning (parameter estimate 0.3172, odds ratio 
1.373, p = 0.0896), suspected secondary sepsis with 
elevated leukocyte count (parameter estimate 
0.5684, odds ratio 1.766, p = 0.0672), and use of 
epinephrine (parameter estimate 0.4204, odds ratio 
1.523, p = 0.0527). Two continuous outcome vari- 
ables were greater in group 2 and reached border- 
line statistical significance: volume of red blood cells 
transfused (p = 0.0998) and duration of ECMO 
support (p = 0.0562). 
Discussion 
The application of ECMO for neonates with 
sepsis has historically been associated with de- 
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creased survival and hemorrhagic omplications. 
Kornhauser and associates 1° reported no survivors 
treated with ECMO for neonatal group B strepto- 
coccal pneumonia, although survival after ECMO 
for other indications (meconium aspiration syn- 
drome) was significantly greater. Despite this nega- 
tive view, other reports have advocated the use of 
ECMO in the management of septic statesJ ~-13 
Hocker and colleagues ~2 presented a retrospective 
experience of patients with early-onset group B 
streptococcal sepsis and observed an 87% survival 
rate in hypotensive, infected patients treated with 
ECMO. Survival was lower in similar patients 
treated conservatively (p = 0.06). Overall, their 
experience with ECMO for sepsis was similar to that 
of neonates upported by ECMO for other reasons. 
Olson, Couch, and McDonald 13 reported on 10 
neonates with sepsis, with a survival from ECMO of 
70%. The most encouraging results have been re- 
ported by McCune and colleagues, ~1 who found a 
survival of 100% for 10 neonates treated with 
ECMO for sepsis. However, these infants did have 
complications, including significantly prolonged 
ventilatory support after ECMO and a greater prev- 
alence of chronic lung disease (30% versus 12%). 
These small retrospective studies are limited and do 
not allow evaluation of the effect of pre-ECMO 
factors or direct comparison with other groups of 
patients treated by ECMO. 
As a result, this study was undertaken to critically 
compare results of ECMO in the septic group with 
those in patients treated for other indications. To 
obtain a sutticient number of patients and to allow 
consideration of other potentially interacting vari- 
ables, we obtained data from the ELSO Registry 
and subjected them to a multivariate analysis. Ac- 
cording to this technique, no significant difference in 
survival was observed between infants treated for 
septic or nonseptic indications (odds ratio = 0.83, 
95% confidence limits 0.60 to 1.14, p = 0.2480). 
These data suggest that earlier concerns questioning 
the efficacy of this modality for septic conditions 
may be unwarranted. Of note, a univariate analysis 
of these same survival data suggested a markedly 
worse survival outcome for patients with sepsis (p = 
0.0002). This illustrates the importance of consider- 
ing the interaction of other factors when addressing 
survival questions. Variables that significantly pre- 
dicted better survival included higher birth weight, 
absence of cardiopulmonary arrest before ECMO, 
higher arterial pH before ECMO, and lower venti- 
lator rate required before ECMO. 
In contradistinction to other reports, 11 general- 
ized bleeding complications were not significantly 
different in the population with sepsis when com- 
pared with the infants without sepsis undergoing 
ECMO in the ELSO Registry. In fact, bleeding at 
surgical sites was more common in the neonates 
without sepsis, a finding likely explained by the 
greater number of operative procedures being per- 
formed with ECMO in the nonseptic group. 9' i4 
Additionally, no significant difference in transfusion 
requirements for red blood cells, fresh frozen 
plasma, or platelets was observed. The causes of 
bleeding complications in patients undergoing 
ECMO are multifactorial and include heparin use, 
quantitative and qualitative platelet function 
changes induced by extracorporeal support, and 
shortened survival time of transfused blood prod- 
ucts in patierrts undergoing~CMO, 15 The~Je factors 
may be more important than the underlying disease 
process. However, thrombotic processes including 
consumptive coagulopathy may be more common in 
the neonates with sepsis. This factor may relate to 
the increased prevalence of intracranial hemorrhage 
and infarction seen in the infants with sepsis. More 
data would be required to determine the cause of 
this finding. 
The septic group was found to have a significantly 
greater incidence of neurologic complications in- 
cluding seizures (odds ratio 1.446, 95% confidence 
limits 1.027 to 2.034, p = 0.0346) and intracranial 
infarct or hemorrhage (odds ratio 2.310, 95% con- 
fidence limits 1.679 to 3.180, p = 0.0001). McCune 
and colleagues H also reported ahigher incidence of 
intracranial hemorrhage in patients with sepsis as 
compared with other patients treated with ECMO 
(40% versus 26%). To combat he risk of bleeding in 
this population, they altered their management 
scheme by reducing heparin doses and maintaining 
higher ECMO flows throughout the period of sup- 
port. This strategy may reduce hemorrhage risk 
without increasing the risk of thrombus formation in 
the cireuit. Thrombotic problems may manifest 
mainly in small vasculature, a factor that may con- 
tribute to the increased incidence of cerebral infarc- 
tion found in the patients with sepsis. The present 
study does not allow analysis of these factors and 
does not differentiate between eurologic problems 
resulting from hemorrhage or thrombosis. 
Lung recovery was found to be less likely in the 
patients with sepsis (p = 0.0185). This lower inci- 
dence of lung recovery in combination with similar 
survivals uggests hat deaths from causes other than 
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lung failure were more prevalent in the nonseptic 
group. The severity of lung damage in the patients 
with sepsis may therefore be greater. McCune and 
associates 11 found pulmonary involvement to be 
more severe in patients with sepsis and proposed 
this to be secondary toadditional structural damage 
not seen with meconium aspiration syndrome or 
respiratory distress yndrome. In contrast, pulmo- 
nary hemorrhage was not different between groups, 
and pneumothorax necessitating treatment and 
other pulmonary problems were more common in 
the patients without sepsis. These latter phenomena 
do not seem to support he hypothesis that pulmo- 
nary damage is more severe in patients with sepsis. 
One may speculate that the pneumothorax compli- 
cation may reflect he larger number of patients in 
the nonseptic group requiring ECMO for primary 
pulmonary processes uch as congenital diaphrag- 
matic hernia or air-leak syndrome. Further studies 
will be required to resolve the issue of the severity of 
lung disease in patients with sepsis. 
An increased incidence of complications in other 
systems was noted in the septic group. The need for 
hemodialysis and hemofiltration was signifieantly 
greater in this group, with serum creatinine leva- 
tion following a similar trend. The requirement for 
nitroglycerin during ECMO was significantly greater 
in the patients with sepsis, implicating a greater 
ineidence of hypertension. Hypernatremia was also 
more common in patients with sepsis, possibly re- 
flecting renal damage. This renal injury may be 
related to the underlying septic state, the treatments 
used for the management of the sepsis, or the 
physiologic response to sepsis or extracorporeal 
support. 
Study limitations. This study represents he larg- 
est collected series of patients with sepsis treated 
with ECMO. Nevertheless, everal important limi- 
tations taust be considered. The study is retrospec- 
tive and spans a period of more than 6 years. ECMO 
practices and reporting patterns may have changed 
over this time period, and results will be biased 
toward centers that report consistently to this vol- 
untary registry. As well, about 12% of each group 
carried a secondary diagnosis of sepsis, a factor not 
considered in the analysis, but one which may 
introduce a degree of uncertainty othe conclusions. 
Furthermore, registry data are incomplete in several 
important areas. Limited information was available 
regarding identification of specific causative organ- 
isms and management schema for sepsis (e.g., anti- 
biotics, steroids) are not described. This information 
may be pertinent to the development of strategies to 
reduce the prevalence and severity of complications. 
Finally, because no long-term follow-up data are 
currently available from the registry, conclusions 
must be restricted to early outcomes only. Inasmuch 
as neurologic omplications were a significant find- 
ing in the septic group, longer-term observation may 
be warranted. As in any new technology, the me- 
chanics of ECMO are evolving. Although 89% of 
patients in this study underwent venoarterial 
ECMO, the current trend is toward increased use of 
venovenous ECMO support, which does not require 
carotid artery ligation. This may influence rates of 
neurologic or other complications. 16 
Although survival is not significantly worse in the 
septic population, strategies are needed to combat 
the variety of complications that are prominent in 
these patients. Close attention to coagulation i di- 
ces may help to limit neurologic omplications seen 
more commonly in the neonates with sepsis. Main- 
tenance of precise fluid balance may help to limit 
renal damage and the need for hemodialysis or 
hemofiltration. This may also influence some of the 
other metabolic abnormalities. Further research 
into the host inflammatory esponse to extracorpo- 
real circulation may yield other approaches that may 
limit or expand on these phenomena. Strategies 
capable of reducing both hemorrhagic and throm- 
botic complications would appear to be particularly 
useful in this subset of patients. 
The progression of sepsis in the neonate is often 
resistant to conventional medical management. In 
contrast to earlier studies, cardiopulmonary support 
in the form of ECMO offers acceptable survival 
rates. Our analysis has demonstrated that a primary 
indication of sepsis does not independently predict a 
lower survival from ECMO when factors such as 
birth weight, cardiac arrest, and ventilator parame- 
ters are considered. Complication rates are higher in 
patients with sepsis as a primary indication for 
ECMO. In particular, neurologic events, renal de- 
terioration, and metabolic problems occur more 
frequently. Bleeding complications are not found 
more frequently in neonates with sepsis. On the 
basis of these data, ECMO should not be withheld 
from neonates solely on the basis of sepsis. Rather, 
management strategies should focus on limiting the 
prevalence or severity of the common complica- 
tions. 
This study emphasizes the value of cooperative 
data registries in evaluation of new technology. 
Pooled data from multiple centers placed into a 
single database allow sufficient numbers for analysis 
of complex questions where multiple variables need 
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to be considered. These registries can provide in- 
sight that any individual center is unlikely to expe- 
rience. 
We are grateful to Tore Delosh and Charles J. H. 
Stolar, MD, of the Extracorporeal Life Support Organi- 
zation for providing access to the El_SO Registry database 
and to Donald Mclnfire, PhD, for reviewing the statistical 
analysis. 
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Discuss ion 
Dr. Julie A. Swain (Las Vegas, Ner.). This report is a 
valuable contribution. Adults obviously do not have meco- 
nium aspiration, so the indi¢ation for ECMO is rar more 
orten sepsis. Do you have any anecdotal data from your 
institution on the results of sepsis and ECMO in adults? I 
know those studies are in progress. 
Dr. Meyer. Our data in the neonatal group have 
prompted us to initiate a review of sepsis in pediatric 
ECMO. It is likely that sepsis represents a larger problem 
in this group and that the results in the pediatric popula- 
tion may more closely relate to the adult experience, 
which is rauch smaller. Sepsis (especially pneumonia) is
the most common primary indication for ECMO in pedi- 
atric cases, and overall survival rates are much lower than 
in neonates. We have also observed that patients in whom 
sepsis develops during ECMO have a significant decrease 
in survival and an increase in bleeding complications. 
Dr. Tore Karl (Melbourne, AustraIia). We would agree 
that sepsis should not preclude candidacy for ECMO in 
either the neonate or the older patient. However, espe- 
cially in the neonatal group, there is a fine line between 
primary sepsis, pulmonary hypertension, meconium aspi- 
ration, and other conditions for which a baby might 
require ECMO. How can one say that the pafient's 
primary problem is sepsis, and how did you do it for this 
study? 
Dr. Meyer. The precision of the primary diagnosis is 
important o the results of this retrospective registry 
analysis. The registry database contains a field for this 
variable that was recorded in all but four of the 6856 cases. 
The primary diagnosis field is rather general, and fre- 
quently in patients with sepsis the organism responsible is 
not recorded. The study is dependent on the accuracy of 
the ELSO Registry database, but so rar as we can deter- 
mine the primary diagnosis eemed weil defined. 
Dr. Karl. You would not know, for example, how many 
of these patients were not considered to have sepsis as a 
primary diagnosis but were receiving broad-spectrum an- 
tibiotics at the time that ECMO was initiated. 
Dr. Meyer. The primary diagnosis was recorded for 
virtually all patients in the ELSO Registry and selected 
among the choices including meconium aspiration syn- 
drome, congenital diaphragmatic hernia with persistent 
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fetal circulation, sepsis, primary pulmonary hypertension 
of the newborn, respiratory distress yndrome, and other 
processes. These diagnoses are generally specific and 
exclusive. For this study, we assumed that clinicians 
focused on the recorded indication as their reason for 
initiating ECMO. The database also included a field for 
secõndary indications, but these were not applied to this 
analysis. 
Dr. Ralph Delius (Iowa City, Iowa). Do you have any 
information on the anticoagulation required in these 
patients? When I was in Ann Arbor we noted that the 
patients with sepsis usually had a coagulopathy. Antico- 
agulation had to be handled carefully to avoid bleeding 
problems. 
With the greater use of the double-lumen cannula, do 
you have any information on venovenous ECMO com- 
pared with venoarterial ECMO? 
Dr. Meyer. Anticoagulation strategies were not specif- 
ically recorded in the ELSO database. Activated clotted 
times were not available to us for this analysis. However, 
we did not find any significant differences in bleeding 
complications per se between the two groups, after con- 
trolling for standard pre-ECMO variables. 
To address the second question, we did not stratify 
patients according to the technique of eannulation. The 
registry data analyzed were eomplete up to June 1993, 
with the majority of patients during this period (89%) 
undergoing ECMO via a venoarterial pproach. Since that 
time, there has been a proliferation of the use of veno- 
venous techniques with double-lumen cannulas, hut our 
information with this technology is limited. A potential 
advantage may be a reduction in the neurologic ompli- 
cations, because the carotid artery is not cannulated. 
However, thrombotic omplications may become more 
prevalent unless higher flow rates are maintained in the 
system. 
Dr. R. Siewers (Pittsburgh, Pa.). It is important to make 
a distinction between ECMO support for neonatal sepsis 
and ECMO support for pediatric sepsis. The relatively 
eneouraging results with ECMO support in the neonatal 
group, greater than 75% survival, has not been matched in 
the older pediatric group, which has shown survivals in the 
40% to 50% fange as documented by the ELSO experi- 
ence. At the Children's Hospital of Pittsburgh, we have 
some serious reservations about applicätion of ECMO 
support in the pediatric age group, distinct from the 
neonatal group, when children are referred for respiratory 
insufficiency on the primary basis of sepsis. I am pleased to 
see that the wealth of data accumulated by ELSO is 
beginning to be presented and discussed in this forum. 
Dr. Meyer. As I indicated, we are now in the process of 
reviewing data in the pediatric age group, where viral 
pneumonia is a more common problem. Survival rates 
appear to be worse in this subpopulation. 
In the neonates, results of ECMO for sepsis are better, 
hut the underlying eause is also different. From the 
minority of patients with organism data available in the 
registry, 74% of neonates placed on ECMO for sepsis had 
group B streptococeal infections. This disease process 
causes physiologie changes consistent with primary pul- 
monary hypertension of the newborn, and ECMO may be 
a more suceessful treatment modality for this disease. 
Appendix A: Outcome variables used in analysis 
General outcome 
Survival 
Recovery of lung function leading to discontinuation f
ECMO 
Duration of ECMO support 
Mechanical complications 
Oxygenator failure 
Raceway rupture 
Other tubing rupture 
Pump malfunction 
Heat exchanger malfunction 
Clots in cireuit 
Air in eircuit 
Craeks in pigtails or conneetors 
Cannula plaeement or reposition problems 
Restrictive sutures 
Hemofilter malfunction 
Kinking in cannula 
Other meehanical problem 
Hemorrhagic complications 
Gastrointestinal hemorrhage neeessitating transfusion 
Bleeding at eannula site 
Bleeding at other surgical site 
Hemolysis 
Other hemorrhagic problem 
Neurologic omplications 
Brain death 
Seizure 
Infarction or hemorrhage by head ultrasound 
Infarction or hemorrhage by computed tomography or
magnetic resonance imaging 
Other neurologic problem 
Renal complications 
Creatinine coneentrations greater than 1.5 mg/dl 
Dialysis or hemofiltration 
Other renal problem 
Cardiopulmonary complications 
Pulmonary hemorrhage 
Cardiopulmonary resuscitation required 
Myocardial stunning 
Cardiac arrhythmias 
Symptomatic patent duetus arteriosus 
Hypertension necessitating vasodilator therapy 
Other cardiopulmonary problem 
Pneumothorax necessitating treatment 
Other pulmonary problem 
Septic omplications 
Culture-proven secondary infeetions 
Secondary infection suspected by elevated white blood 
eell count 
Other infectious problem 
Transfusion requirements 
Volume of packed red blood cells transfused 
Volume of fresh frozen plasma transfused 
Volume of platelets administered 
Metabolic omplications 
Serum potassium level less than 2.5 mEq/L 
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Serum potassium level greater than 6.0 mEg/L 
Serum sodium level less than 125 mEq/L 
Serum sodium level greater than 150 mEq/L 
Serum calcium level less than 6 mg/dl 
Serum calcium level greater than 12 mg/dl 
Blood glucose level less than 40 mg/dl 
Blood glucose level greater than 240 mg/dl 
Other blood sugar problems 
pH less than 7.20 
pH greater than 7.60 
Hyperbilirubinemia 
Other metabolic problems 
Drug requirements 
Dopamine administered 
Dobutamine administered 
Tolazoline administered 
Nitroprusside administered 
Isoproterenol administered 
Prostaglandin E administered 
Epinephrine administered 
Nitroglycerin administered 
Other vasoactive drug administered 
Surfactant administered 
Bicarbonate administered 
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Appendix B: Pre-ECMO variables used in 
evaluation 
General 
1. Patient age at time of ECMO 
2. Patient sex 
3. Birth weight 
4. Cardiopulmonary arrest before ECMO 
Most recent arteriaI blood gas before ECMO 
5. pH 
6. Carbon dioxide tension 
7. Oxygen tension 
8. Bicarbonate 
9. Saturation 
Most recent ventilator settings before ECMO 
10. Ventilator ate 
11. Inspired oxygen fraction 
12. Peak inspiratory pressure 
13. Positive end-expiratory pressure level 
14. Mean airway pressure 
15. Oxygenation index (inspired oxygen fraction x 
mean airway pressure × 100/arterial oxygen ten- 
sion) 
